{"version":"1.0","type":"link","title":"Comment on \"Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study\".","author_name":"Wang H 외","author_url":"https://prs-insight.online/author/Wang%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/111929","thumbnail_width":1200,"thumbnail_height":630}